+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating DT120, a psychoactive drug acting mainly on serotonin 2A receptors, for treating adults aged 18 to 74 with major depressive disorder MDD. This Phase 3 trial compares DT120 to placebo over 12 weeks in a double-blind, randomized, and triple-blind design to assess its efficacy and safety. Participants must have a confirmed diagnosis of MDD with specific symptom severity and duration, without major psychiatric or unstable medical conditions. The study includes a 12-week double-blind period where participants receive a single dose of either DT120 at one of two dose levels or placebo. This is followed by a 40-week open-label extension phase where all participants may receive DT120 with monitoring for retreatment based on safety and symptoms. The trial evaluates multiple outcomes related to depression severity, symptom improvement, anxiety, sexual function, quality of life, and work productivity. Participants will undergo regular assessments including depression rating scales like MADRS and CGI, anxiety scales, and questionnaires on sexual functioning and daily activity impact. Monitoring continues throughout the extension phase to assess treatment durability and response. The total participation may last up to 52 weeks, with evaluations at several timepoints to understand treatment effects and safety over both study phases.

Age: 18Years - 74YearsAll GendersPhase 3
30 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of Xanomeline and Trospium Chloride in children and adolescents with psychiatric disorders, including schizophrenia and autism-related irritability. This Phase 3, open-label study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, aiming to understand how these drugs affect young patients over an extended period. Participants will receive specified doses of KarXT or the combination of KarXT and KarX-EC depending on their condition. The study is non-randomized and open-label, meaning all participants receive the study treatment without placebo comparison. The treatment period can last up to 56 weeks, during which the safety and side effects of the medications will be closely monitored. Throughout the study, participants will undergo regular assessments to monitor treatment emergent adverse events, serious adverse events, and special interest adverse events. Additional evaluations include symptom assessments using scales like the Columbia Suicide Severity Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes-Akathisia Rating Scale. The study involves continuous safety monitoring and lasts up to 56 weeks, with follow-up to evaluate both tolerability and any psychiatric symptoms.

Age: 5Years - 17YearsAll GendersPhase 3
104 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial is designed to test how well TSND-201 works compared to a placebo in treating PTSD symptoms. Eligible participants must have a current diagnosis of PTSD lasting at least six months and have tried previous treatments such as medication or trauma-focused psychotherapy. Participants will be randomly assigned to one of three groups two different doses of TSND-201 or a placebo. Each participant will take capsules orally once a week for four consecutive weeks during the Treatment Period. After completing treatment, participants will enter an 8-week Follow-up Period to monitor their progress without additional treatment. Throughout the study, participants will be assessed using the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD symptom severity from baseline up to 12 weeks. Regular interviews and questionnaires will be completed to track safety and efficacy. The study aims to complete by December 2027, with careful monitoring to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
37 locations
E

Actively Recruiting

Researchers are evaluating LPCN 1154A as a possible treatment for postpartum depression PPD in women with severe symptoms. This phase 3 trial aims to find out if LPCN 1154A can reduce depressive symptoms and how well it is tolerated, including potential side effects. Participants receive either oral LPCN 1154A tablets or placebo tablets for 48 hours. The study is randomized and blinded to compare these two groups in parallel. The treatment phase lasts for 48 hours. During the study, participants will be assessed for changes in depression severity using the Hamilton Depression Rating Scale HAM-D from baseline to hour 60, along with other measures at hour 12 and day 30. Safety and side effects are monitored throughout. The participation spans from screening through treatment and follow-up assessments.

Age: 15Years - 45YearsFEMALEPhase 3
16 locations
E

Actively Recruiting

Researchers are evaluating the RestoreX penile traction device to see if it helps preserve erectile function in men undergoing robotic-assisted prostatectomy with bilateral nerve preservation and moderate or better baseline erectile function. This study aims to confirm previous findings that RestoreX may improve erectile function and penile length after prostatectomy, conditions that often lead to sexual dysfunction and other complications. The trial is a large, multi-center, randomized controlled study with a prevention focus. Participants in the treatment group will use the RestoreX device for 30 to 60 minutes daily, 5 to 7 days per week, starting one month after prostatectomy and continuing for five months. After six months, all participants may choose to use the device for an additional three months during an open-label phase. The device provides direct traction to the penis and is classified as a class I orthotic device, previously studied for safety and efficacy in improving erectile function and penile length. Throughout the study, participants will be assessed using the International Index of Erectile Function at 3, 6, and 9 months, with the primary outcome measured at 6 months. Researchers will monitor changes in erectile function and other questionnaire outcomes, as well as any adverse events. The study is scheduled for three years to allow sufficient enrollment and follow-up, with participant involvement spanning the treatment and open-label phases.

Age: 18Years +MALEPhase Not Applicable
4 locations
N

Actively Recruiting

Healthy Volunteer

This observational study aims to create a large national registry to evaluate the safety and effectiveness of various therapies used to treat ejaculatory and orgasmic dysfunctions in men. The study includes men receiving treatment for these conditions as well as their sexual partners. The research is designed to collect key outcome data to better understand treatment impacts over time. Participants will be invited to join the registry through their local healthcare providers. Once enrolled, they will complete questionnaires about their diagnosis and treatment effectiveness at the start of the study, then every three months for one year, and subsequently every six months for two more years. Sexual partners of affected men can also participate and follow the same questionnaire schedule. Throughout the study, participants will provide information via surveys about their symptoms and treatment outcomes at regular intervals. The main focus is to monitor outcomes over a three-year period. The study is sponsored by the Charitable Union for the Research and Education of Peyronies Disease and aims to gather comprehensive data to improve understanding of these sexual dysfunctions.

Age: 18Years +All Genders
1 location
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
G

Actively Recruiting

Researchers are studying the long-term safety of the drug NBI-1117568 in adults diagnosed with schizophrenia. This phase 3, open-label trial aims to understand how well participants tolerate this medication when taken daily over an extended period. The study is sponsored by Neurocrine Biosciences and focuses on monitoring treatment-emergent adverse events. Participants will receive NBI-1117568 orally once a day for up to 36 months. This single-group study does not include a placebo or comparator arm. The treatment duration allows researchers to assess safety and tolerability during continuous daily use over three years. During the study, participants will have regular assessments to monitor any adverse effects associated with the drug. Researchers will track the number of participants experiencing treatment-emergent adverse events throughout the 36-month period. The study includes adults aged 18 to 65 years who have a primary diagnosis of schizophrenia and reside in stable housing, and it excludes those with certain medical conditions or substance use disorders. Participants will be closely observed to ensure adherence to the study protocol and safety monitoring.

Age: 18Years - 65YearsAll GendersPhase 3
61 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of RE104 for Injection in treating adults with Generalized Anxiety Disorder GAD. This Phase 2 study compares the effects of a single or repeated dose of RE104 to a placebo, aiming to reduce anxiety symptoms as measured by the Hamilton Anxiety Rating Scale and other depression and anxiety assessments. Participants must have a diagnosis of GAD and meet specific health criteria to join. Participants will receive either a single subcutaneous injection of 30 mg RE104 or a placebo injection of 0.9% sodium chloride. The study includes two dosing sessions spaced three weeks apart to observe if one or two doses provide symptom relief. Both groups are monitored under a randomized, double-blind design where neither participants nor researchers know who receives the active drug or placebo. Throughout the study, participants will attend visits at various time points including baseline and weeks 1, 2, 4, 8, and 12 for assessments. These include symptom rating scales for anxiety and depression, monitoring for adverse events, and safety evaluations. The primary outcome is the change in anxiety scores at week 4. Follow-up continues for 12 weeks post-dose to evaluate ongoing effects and safety. Total participation lasts several months, ensuring close monitoring and support.

Age: 18Years - 74YearsAll GendersPhase 2
28 locations
P

Actively Recruiting

Researchers are evaluating whether adding ABX-002 to an existing antidepressant treatment can improve depression symptoms in adults with moderate to severe major depressive disorder who have not adequately responded to their current antidepressant. This Phase 2, double-blind, placebo-controlled study aims to compare ABX-002 against a placebo alongside stable doses of selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors SSRISNRI. The study is sponsored by Autobahn Therapeutics, Inc. Participants will be randomly assigned to one of two groups one receiving ABX-002 oral solution and the other receiving a placebo, both taken as a 1-mL oral solution on an empty stomach each morning followed by water. All participants will continue their stable SSRI or SNRI antidepressant dose throughout the study. The study includes a screening period of about 35 days, a 42-day treatment period, a 2-week safety follow-up after dosing, and an additional 6-month targeted safety follow-up. During the study, participants will undergo assessments including the 17-item Hamilton Rating Scale for Depression HAMD-17 to measure changes in depression symptoms, as well as other scales like the Clinical Global Impression of Severity and Sheehan Disability Scale. Safety and tolerability will be monitored through adverse event reporting. The total participation time spans the screening through the extended safety follow-ups, with various evaluations conducted at specified intervals to track treatment effects and safety.

Age: 18Years - 65YearsAll GendersPhase 2
50 locations

1-10 of 11

1